title: Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens.
authors: B C
authors: BC
authors: Kraljacic
authors: M
authors: M
authors: Arguello
authors: A
authors: A
authors: Amri
authors: G
authors: G
authors: Cormack
authors: K
authors: K
authors: Borden
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000494:pharmacology*; D001667:Binding, Competitive; D017322:Clinical Trials, Phase II as Topic; D003561:Cytarabine / Q000494:pharmacology*; D004357:Drug Synergism; D039561:Eukaryotic Initiation Factor-4E / Q000037:antagonists & inhibitors*; D006801:Humans; D015255:Idarubicin / Q000494:pharmacology*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000494:pharmacology*; D012315:RNA Caps / Q000037:antagonists & inhibitors / Q000378:metabolism; D012254:Ribavirin / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D000077157:Sorafenib; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014410:Tumor Stem Cell Assay
chemical_list: D001557:Benzenesulfonates; D039561:Eukaryotic Initiation Factor-4E; D010671:Phenylurea Compounds; D011725:Pyridines; D012315:RNA Caps; D003561:Cytarabine; D009536:Niacinamide; D012254:Ribavirin; D000077157:Sorafenib; D015255:Idarubicin